CSL (OTCMKTS:CSLLY) Shares Gap Down – Here’s What Happened

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) shares gapped down prior to trading on Tuesday . The stock had previously closed at $57.51, but opened at $55.36. CSL shares last traded at $57.6550, with a volume of 8,780 shares trading hands.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. Zacks Research upgraded shares of CSL from a “strong sell” rating to a “hold” rating in a research note on Monday, December 29th. Canaccord Genuity Group upgraded shares of CSL from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 28th. Two research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy”.

CSL Price Performance

The company has a debt-to-equity ratio of 0.50, a current ratio of 2.46 and a quick ratio of 1.12. The stock has a fifty day moving average price of $58.78 and a 200 day moving average price of $69.51.

CSL Company Profile

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.